Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • IRAK1/4
      • RIPK1
      • COVID-19
    • Partnered Programs
      • BerGenBio
      • Daiichi-Sankyo
      • Forma
      • Grifols
      • Kissei
      • Lilly
      • Medison
      • Knight
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Events & Presentations

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts

Fourth Quarter and Full Year 2022 Financial Results

Mar 7, 2023 4:30 pm EDT
Earnings Release
PDF HTML
Audio
Earnings Webcast
Earnings Presentation
PDF
10-K Filing
PDF HTML
XBRL
ZIP XLS HTML
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2023 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

REZLIDHIA is a trademark of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin